论文部分内容阅读
进展期胃癌术后5年生存率低,主要原因是胃癌术后腹腔内游离癌细胞和残存微小病灶形成腹腔种植而复发,或腹腔内游离癌细胞经门静脉系统导致肝转移[1]。腹腔热灌注化疗利用肿瘤细胞比正常细胞更不耐热以及腹腔内直接给药比静脉给药药物浓度高出数倍的原理,对控制胃癌术后的复发和转移有一定的临床价值[2]。国内应用腹腔热灌注化疗联合静脉化疗能降低术后复发率和转移率而提高生存率,得到了肯定的效果[3]。
The 5-year survival rate of advanced gastric cancer is low, mainly due to the recurrence of free intra-abdominal cancer cells and residual micro-lesions after abdominal surgery, or the intra-abdominal free cancer cells leading to liver metastasis via the portal vein system [1]. Intraperitoneal hyperthermic perfusion chemotherapy utilizes the principle that tumor cells are more thermolabile than normal cells and intraperitoneal administration is several times higher than that of intravenous drug administration, which has certain clinical value in controlling the recurrence and metastasis of gastric cancer [2] . Domestic application of intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy can reduce postoperative recurrence rate and metastasis rate and improve survival rate, got a positive effect [3].